ATE335759T1 - Verfahren und zusammensetzungen für die diagnose und die behandlung von krankheiten, die mit eisenüberschuss oder eisenmangel assoziiert sind. - Google Patents

Verfahren und zusammensetzungen für die diagnose und die behandlung von krankheiten, die mit eisenüberschuss oder eisenmangel assoziiert sind.

Info

Publication number
ATE335759T1
ATE335759T1 AT98930243T AT98930243T ATE335759T1 AT E335759 T1 ATE335759 T1 AT E335759T1 AT 98930243 T AT98930243 T AT 98930243T AT 98930243 T AT98930243 T AT 98930243T AT E335759 T1 ATE335759 T1 AT E335759T1
Authority
AT
Austria
Prior art keywords
iron
diagnosis
compositions
treatment
methods
Prior art date
Application number
AT98930243T
Other languages
English (en)
Inventor
John N Feder
Pamela J Bjorkman
Randall C Schatzman
Original Assignee
Bio Rad Laboratories
California Inst Of Techn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Rad Laboratories, California Inst Of Techn filed Critical Bio Rad Laboratories
Application granted granted Critical
Publication of ATE335759T1 publication Critical patent/ATE335759T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT98930243T 1997-06-13 1998-06-12 Verfahren und zusammensetzungen für die diagnose und die behandlung von krankheiten, die mit eisenüberschuss oder eisenmangel assoziiert sind. ATE335759T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87601097A 1997-06-13 1997-06-13

Publications (1)

Publication Number Publication Date
ATE335759T1 true ATE335759T1 (de) 2006-09-15

Family

ID=25366786

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06016507T ATE462717T1 (de) 1997-06-13 1998-06-12 Verfahren und zusammensetzungen für die diagnose und die behandlung von krankheiten, die mit eisenüberschuss oder eisenmangel assoziiert sind
AT98930243T ATE335759T1 (de) 1997-06-13 1998-06-12 Verfahren und zusammensetzungen für die diagnose und die behandlung von krankheiten, die mit eisenüberschuss oder eisenmangel assoziiert sind.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06016507T ATE462717T1 (de) 1997-06-13 1998-06-12 Verfahren und zusammensetzungen für die diagnose und die behandlung von krankheiten, die mit eisenüberschuss oder eisenmangel assoziiert sind

Country Status (8)

Country Link
US (3) US6391852B1 (de)
EP (2) EP0988316B1 (de)
JP (1) JP2002506438A (de)
AT (2) ATE462717T1 (de)
AU (1) AU745403B2 (de)
CA (1) CA2293808C (de)
DE (2) DE69835519T2 (de)
WO (1) WO1998056814A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026116B1 (en) * 1996-04-04 2006-04-11 Bio-Rad Laboratories, Inc. Polymorphisms in the region of the human hemochromatosis gene
US6140305A (en) * 1996-04-04 2000-10-31 Bio-Rad Laboratories, Inc. Hereditary hemochromatosis gene products
US6849399B1 (en) * 1996-05-23 2005-02-01 Bio-Rad Laboratories, Inc. Methods and compositions for diagnosis and treatment of iron misregulation diseases
AU745403B2 (en) 1997-06-13 2002-03-21 Bio-Rad Laboratories, Inc. Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
US6284732B1 (en) * 1998-12-18 2001-09-04 Bio-Rad Laboratories, Inc. Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases
US7160855B2 (en) * 2002-03-14 2007-01-09 Children's Hospital & Research Center At Oakland Enhancement of iron chelation therapy
KR101377467B1 (ko) 2010-02-19 2014-03-25 도버 케미칼 코포레이션 알킬페놀이 없는 액상 고분자형 폴리아인산염 중합체 안정화제
US9982112B2 (en) 2010-02-19 2018-05-29 Dover Chemical Corporation Copolymeric polyphosphite polymer stabilizers
US8981042B2 (en) 2010-02-19 2015-03-17 Dover Chemical Corporation Cycloaliphatic polyphosphite polymer stabilizers
US9745425B2 (en) 2012-06-22 2017-08-29 Dover Chemical Corporation Cycloaliphatic polyphosphite

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE208609C (de)
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4434156A (en) 1981-10-26 1984-02-28 The Salk Institute For Biological Studies Monoclonal antibodies specific for the human transferrin receptor glycoprotein
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
GB8325494D0 (en) 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
US4912118A (en) 1983-09-23 1990-03-27 National Research Development Corporation Pharmaceutical compositions
US4711845A (en) 1984-08-31 1987-12-08 Cetus Corporation Portable temperature-sensitive control cassette
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
MX12394A (es) 1987-07-23 1993-12-01 Ciba Geigy Ag Procedimiento par la obtencion de carbamatos de polietilenglicol.
IL84331A0 (en) 1987-11-02 1988-04-29 Yissum Res Dev Co Pyridoxyl hydrazone derivatives and pharmaceutical compositions containing the same
ES2042061T3 (es) 1988-06-08 1993-12-01 Ciba-Geigy Ag Procedimiento para la obtencion de derivados carbamoilados del acido hidroxamico.
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5582979A (en) 1989-04-21 1996-12-10 Marshfield Clinic Length polymorphisms in (dC-dA)n.(dG-dT)n sequences and method of using the same
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
IL91047A (en) 1989-07-19 1993-06-10 Yissum Res Dev Co Zinc complexes for the treatment of free radical- induced diseases
US5607437A (en) 1990-07-12 1997-03-04 University Of Miami Instruments for use in performing gel injection adjustable keratoplasty
FR2680687A1 (fr) 1991-08-29 1993-03-05 Etienne Marie Christine Compositions pharmaceutiques homeopathiques utilisees pour la fabrication de medicaments destines au traitement des maladies causees par des erreurs metaboliques et au traitement des maladies virales.
DE69226940T2 (de) 1991-12-02 1999-05-27 Oriental Yeast Co. Ltd., Tokio/Tokyo Verfahren und Reagenz zur Bestimmung von Serumeisen oder von der Bindungsfähigkeit des ungesättigten Eisens durch Verwendung von Akonitase
GB9209078D0 (en) 1992-04-27 1992-06-10 Hider Robert C Pharmaceutical compositions
EP1143253A1 (de) 1992-07-10 2001-10-10 University Of British Columbia Verwendung von p97 und Eisenbindungsproteinen als diagnostische und therapeutische Wirkstoffe
WO1994011367A1 (en) 1992-11-16 1994-05-26 University Of Florida Research Foundation Inc. 2-(pyrid-2'-yl)-2-thiazoline-4(s)-carboxylic acid derivatives
ATE172985T1 (de) 1993-02-09 1998-11-15 Bayer Ag Sulfonamidaminomethylenderivate als immunsuppressiva
EP0610745A3 (en) 1993-02-09 1994-09-28 Miles Inc Novel aminomethylene derivatives as immunosuppressants.
US5385918A (en) 1993-02-09 1995-01-31 Miles Inc. Aminomethylene-peptides as immunosuppressants
AU3920293A (en) 1993-03-16 1994-10-11 Board Of Regents Of The University Of Nebraska, The Novel metal binding agents, and methods and compositions for their use to treat metal toxicity
JP3585180B2 (ja) 1993-05-11 2004-11-04 三菱化学株式会社 新規なヒトタンパク質およびそれをコードする遺伝子
DE4327226A1 (de) 1993-08-13 1995-02-16 Hoechst Ag Chelatoren, ihre Herstellung aus den Antibiotika Salmycin A, B oder C und deren Verwendung
WO1995016663A1 (en) 1993-12-16 1995-06-22 Ciba-Geigy Ag N,n'-bis(2-hydroxybenzyl)ethylenediamine-n,n'-diacetic acid derivatives as chelating agents
KR0136993B1 (ko) 1994-09-13 1998-04-24 김주용 비휘발성 메모리 소자 제조방법
US5674681A (en) 1994-12-06 1997-10-07 Rothenberg; Barry E. Methods to identify hemochromatosis
US5705343A (en) 1995-05-08 1998-01-06 Mercator Genetics, Inc. Method to diagnose hereditary hemochromatosis
US5753438A (en) 1995-05-08 1998-05-19 Mercator Genetics, Inc. Method to diagnose hereditary hemochromatosis
US5872237A (en) 1996-04-04 1999-02-16 Mercator Genetics, Inc. Megabase transcript map: novel sequences and antibodies thereto
US5712098A (en) 1996-04-04 1998-01-27 Mercator Genetics Hereditary hemochromatosis diagnostic markers and diagnostic methods
US6025130A (en) * 1996-04-04 2000-02-15 Mercator Genetics, Inc. Hereditary hemochromatosis gene
US6140305A (en) * 1996-04-04 2000-10-31 Bio-Rad Laboratories, Inc. Hereditary hemochromatosis gene products
US6849399B1 (en) 1996-05-23 2005-02-01 Bio-Rad Laboratories, Inc. Methods and compositions for diagnosis and treatment of iron misregulation diseases
EP0960114B1 (de) 1996-10-01 2007-09-19 Bio-Rad Laboratories, Inc. Polymorphismus und neue gene in der region des menschlichen hemochromatosisgens
AU745403B2 (en) 1997-06-13 2002-03-21 Bio-Rad Laboratories, Inc. Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
US6284732B1 (en) 1998-12-18 2001-09-04 Bio-Rad Laboratories, Inc. Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases

Also Published As

Publication number Publication date
US7374892B2 (en) 2008-05-20
EP0988316A1 (de) 2000-03-29
WO1998056814A1 (en) 1998-12-17
US6391852B1 (en) 2002-05-21
AU7968198A (en) 1998-12-30
EP0988316B1 (de) 2006-08-09
EP1757614B1 (de) 2010-03-31
US7119170B2 (en) 2006-10-10
EP0988316A4 (de) 2003-07-09
CA2293808C (en) 2006-10-17
ATE462717T1 (de) 2010-04-15
US20060287236A1 (en) 2006-12-21
CA2293808A1 (en) 1998-12-17
US20030073627A1 (en) 2003-04-17
JP2002506438A (ja) 2002-02-26
DE69841593D1 (de) 2010-05-12
DE69835519D1 (de) 2006-09-21
EP1757614A1 (de) 2007-02-28
DE69835519T2 (de) 2007-04-05
AU745403B2 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
EP0792156A4 (de) Verfahren zur vorbeugung oder behandlung von vaskulären hämorragien und der alzheimerischen krankheit
DE69536017D1 (de) Methoden und zusammensetzungen für die behandlung von glomerulonephritis
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
DE3686362D1 (de) Verfahren zur behandlung von magen-darmstoerungen.
DE3779149D1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
DE69633717D1 (de) Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
DE69628912D1 (de) Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer
DE69530933D1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
ATE342067T1 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
DE69841593D1 (de) Verfahren und Zusammensetzungen für die Diagnose und die Behandlung von Krankheiten, die mit Eisenüberschuss oder Eisenmangel assoziiert sind
ZA200107283B (en) Vascular adhesion molecules and modulation of their function.
DE69729954D1 (de) Identifizierungsverfahren für Substanzen die an das Pyk2 Polypeptid binden
EP1109929A4 (de) Verfahren zur diagnose von magensalz-schwundsyndrom und alzheimerscher krankheit und behandlungsverfahren
DE69329656D1 (de) Methoden zur detektion und behandlung von individuen mit abnormalen hla-a2/tyrosinase-peptidantigenen exprimierenden zellen
ATE454451T1 (de) Methode zur behandlung von muskelkrankheiten
ATE213163T1 (de) Verfahren zur behandlung von motorischen defiziten
ES2057572T3 (es) Agentes de reconocimiento.
DE59008012D1 (de) Mittel zur Behandlung von Leder und Pelzen.
ATE526995T1 (de) Stereoisomers von fettsäureanalogen für diagnostische bildgebung
PT870036E (pt) Α-n-acetilglucosaminidase de mamífero sintética e sequências genéticas codificando a mesma
ATE321135T1 (de) Verfahren zur diagnose und behandlung neurologischer erkrankungen
DE69821970D1 (de) Verwendung von CITICOLINE ZUR BEHANDLUNG VON MULTIPLER SKLEROSE
ATE203680T1 (de) Konjugat zur behandlung von entzündungserkrankungen
DE69013139D1 (de) Mittel zur Vorbeugung, Diagnose und Therapie von rheumatischen, autoimmunen, Haut- und Bindegewebekrankheiten von unbekannter Aetiologie und Verfahren zu seiner Herstellung und Verwendung.
DE68914886D1 (de) Mittel zur Behandlung von Raynaud's Krankheit.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties